Aclaris Therapeutics (ACRS) Non Operating Income (2015 - 2026)

Aclaris Therapeutics' Non Operating Income history runs 6 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• On a quarterly basis, Non Operating Income fell 21.04% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $10.8 million, a 0.5% change from a year earlier, with the FY2025 full-year figure at $11.5 million, up 16.06% from the prior year.
• Non Operating Income eased to $2.4 million in Q1 2026 per ACRS's latest filing, from $2.9 million in the prior quarter.
• Across five years, Non Operating Income topped out at $3.1 million in Q4 2024 and bottomed at $1.9 million in Q2 2024.
• The 4-year median for Non Operating Income is $2.5 million (2025), against an average of $2.6 million.
• Across the five-year window, Non Operating Income jumped 59.48% in 2025 and decreased 21.04% in 2026, its largest moves.
• Year by year, Non Operating Income stood at $2.2 million in 2023, then soared by 42.67% to $3.1 million in 2024, then slipped by 5.89% to $2.9 million in 2025, then slipped by 19.43% to $2.4 million in 2026.
• Per Business Quant, the three latest ACRS Non Operating Income figures stand at $2.4 million (Q1 2026), $2.9 million (Q4 2025), and $2.5 million (Q3 2025).